Hikma Pharmaceuticals Forecast, price target & analysts
Hikma Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Hikma Pharmaceuticals Classifications & Recommendation:
Hikma Pharmaceuticals Price Target
| Target Price | £26.19 |
| Price | £17.53 |
| Potential |
49.39%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Hikma Pharmaceuticals 2026 .
The average Hikma Pharmaceuticals target price is £26.19.
This is
49.39%
register free of charge
£29.93
70.71%
register free of charge
£21.92
25.03%
register free of charge
|
|
| A rating was issued by 20 analysts: 16 Analysts recommend Hikma Pharmaceuticals to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Hikma Pharmaceuticals stock has an average upside potential 2026 of
49.39%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2030
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion £ | 2.37 | 2.57 |
| 9.77% | 8.43% | |
| EBITDA Margin | 22.85% | 26.26% |
| 7.49% | 14.95% |
14 Analysts have issued a sales forecast Hikma Pharmaceuticals 2025 . The average Hikma Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an Hikma Pharmaceuticals EBITDA forecast 2025. The average Hikma Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share £ | 1.21 | 1.75 |
| 89.06% | 44.63% | |
| P/E | 10.10 |
14 Analysts have issued a Hikma Pharmaceuticals forecast for earnings per share. The average Hikma Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Hikma Pharmaceuticals...
Current Hikma Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| Deutsche |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| JP Morgan Cazenove |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| JP Morgan Cazenove |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Jan 29 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
Deutsche:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
JP Morgan Cazenove:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
JP Morgan Cazenove:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Jan 29 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
